FDA Panel Unanimously Backs Moderna’s Breakthrough mRNA Flu Vaccine Amid Political Turbulence

In a landmark decision that could reshape seasonal respiratory protection, the FDA’s top vaccine advisory committee voted unanimously on June 18, 2026, to recommend Moderna’s mRNA-based influenza vaccine (mFlusiva) for adults aged 50 years and older. The 9-0 vote by the Vaccines and Related Biological Products Advisory Committee (VRBPAC) marks the first time the panel has reviewed a new vaccine application since May 2023.¹

The vaccine utilizes the same mRNA technology that powered the rapid development of COVID-19 immunizations. For public health experts, the recommendation is a “breath of fresh air” following a period of intense political scrutiny regarding vaccine research under the current administration. The approval process itself has been rocky, including an initial refusal by the FDA to review the application in February 2024 before the agency reversed course 2 weeks later.^1,2

Clinical Data: A 26.6% Boost in Efficacy

The committee’s recommendation was heavily supported by robust phase 3 clinical trial data published in the New England Journal of Medicine (NEJM). The FLUENT trial (NCT06602024) was a double-blind, active-controlled study involving 40,703 participants aged 50 years and older. Half of the participants received the investigational mRNA-1010 vaccine, whereas the other half received a licensed standard-dose comparator.³

The results demonstrated that mRNA-1010 met all primary efficacy end points, achieving noninferiority, superiority, and higher-level superiority over the standard vaccine. Specifically, the mRNA vaccine showed a relative vaccine efficacy of approximately 26.6% against protocol-defined influenza-like illness caused by influenza A or B.³

Researchers noted that the mRNA platform appeared to produce a longer-lasting immune response and antibodies that recognized a broader range of flu strains than current traditional vaccines. Furthermore, the platform allows for a significant compressed production timeline, shrinking the window to target specific emerging strains from 6 months down to just 2 or 3 months.¹

Regarding safety, the NEJM data showed that solicited adverse reactions were more frequent with the mRNA vaccine, including injection-site pain (65.8%), fatigue (45.1%), and headache (37.8%), but most reactions were mild to moderate and transient. Both the FDA and Moderna emphasized that the vaccine does not enter the cellular nucleus or interact with human DNA, addressing common public misconceptions.^1,3

The AAP Legal Dispute: A Hurdle for ACIP

Although the FDA’s VRBPAC has signaled its approval, a secondary hurdle remains: the CDC’s Advisory Committee on Immunization Practices (ACIP). This panel is responsible for determining exactly how a vaccine should be used and whether it will be covered by insurance; however, the ACIP is currently embroiled in its own legal and political battle.¹

US Department of Health and Human Services (HHS) Robert F. Kennedy, Jr, recently claimed on social media that the ACIP is unable to carry out its core responsibilities, including reviewing newly approved vaccines for the fall flu season. Kennedy cited a recent court order that he contends left the committee “without a quorum.”⁴ This follows a March ruling by a federal judge in Boston that temporarily blocked Kennedy from cutting the number of recommended childhood vaccines and suggested he may have violated federal procedures when revamping the ACIP last year with several antivaccine voices.⁴

The American Academy of Pediatrics (AAP) has disputed Kennedy’s claims, calling them a “red herring.”⁵ AAP President Andrew Racine, MD, PhD, stated that the federal government maintains the power to “restore a lawful ACIP” and schedule a meeting at any time. Richard Hughes IV, legal counsel for the AAP, argued that the HHS Secretary is using a “self-created crisis” to rush the reinstatement of appointments that the court previously deemed likely unlawful.⁴

Impact on the Fall Flu Season

The outcome of this dispute is critical for the rollout of mFlusiva. Without a recommendation from ACIP, insurers may not be required to cover the vaccine, and clinical guidance for providers will remain in limbo. During the 2025-2026 flu season, the US saw roughly 32 million cases and 24,000 deaths, highlighting the urgency of effective vaccination strategies.¹

If the legal logjam is cleared and the ACIP is lawfully reconvened, Moderna says the new mRNA vaccine could be available as early as this coming fall. For now, the medical community remains hopeful that the evidence-based success seen at the FDA will eventually reach the public despite the ongoing litigation.

REFERENCES

1. Kim J. Key FDA committee unanimously recommends its first vaccine since 2023. NPR. June 18, 2026. Accessed June 19, 2026. https://www.npr.org/2026/06/18/nx-s1-5863570/flu-vaccine-mrna-moderna-fda

2. Lupkin S. FDA reverses course on Moderna flu shot. NPR. February 18, 2026. Accessed June 19, 2026. https://www.npr.org/2026/02/18/nx-s1-5718116/fda-moderna-mrna-flu-shot

3. Leroux-Roels I, Huang G, Ferguson M, et al. Efficacy and safety of an mRNA seasonal influenza vaccine in adults. N Engl J Med. 2026;394:1803-1813. doi:10.1056/NEJMoa2516491

4. Henderson J. AAP disputes Kennedy’s claim that vaccine panel can’t meet ahead of flu season. MedPage Today. June 16, 2026. Accessed June 19, 2026. https://www.medpagetoday.com/publichealthpolicy/washington-watch/121790

5. AAP statement in response to HHS request to appeal vaccine lawsuit. News release. American Academy of Pediatrics. June 16, 2026. Accessed June 19, 2026. https://www.aap.org/en/news-room/news-releases/aap/2026/aap-statement-in-response-to-hhs-request-to-appeal-vaccine-lawsuit/